Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial
I'm PortAI, I can summarize articles.
Roche's experimental multiple sclerosis drug fenebrutinib has met its main goal in a late-stage trial for primary progressive multiple sclerosis (PPMS). The Phase III study showed a 12% reduction in the risk of worsening disability compared to Roche's Ocrevus, the only approved treatment for PPMS. The drug is the first in over a decade to demonstrate a reduction in disability progression in PPMS. Roche plans to seek regulatory approval after additional Phase III data from a relapsing MS trial, expected in early 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments